Work

Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review

Year: 2022

Type: review

Source: Cardiovascular Drugs and Therapy

DOI: 10.1007/s10557-021-07293-w

Authors: S. Bellosta, C. Rossi, A. S. Alieva, A. L. Catapano, A. Corsini, A. Baragetti

Institutions: University of Milan, Federal Almazov North-West Medical Research Centre, MultiMedica

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Kowa Company, Fondazione Cariplo, Daiichi-Sankyo, Ministero della Salute, Fondazione Umberto Veronesi, Servier, Horizon 2020 Framework Programme, Daiichi Sankyo Europe

Awards: G1245513056, G1258120513, G1905476930, Immunometabolic effects of apolipoprotein E: focus on the modulation of cholesterol metabolism in antigen presenting cells, G3027600238, G309306823, G3171160929, G342161892, G3742022484, G4441702973, Humoral innate immunity in the regulation of tissue repair and metabolism in aging, G506836765, G5080221447, G5300162077, G5755199854, G833287072, G8464016131, G8756419255, G965409560

OpenAlex ID: W4205899727

FWCI: 0.43

Cites: 85

Cited by: 11

Related to: 10